CRMD Stock Risk & Deep Value Analysis
CorMedix Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About CRMD Stock
We analyzed CorMedix Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CRMD through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
CRMD Risk Analysis & Red Flags
What Could Go Wrong
The primary risk stems from the commercialization of DefenCath and the Melinta portfolio. Despite strong Q1 2026 results, any failure to sustain the rapid adoption of DefenCath or effectively integrate and grow the Melinta products could lead to the company missing its raised FY2026 revenue guidance of $325M-$345M, potentially causing a significant de-rating due to a perceived slowdown in growth momentum.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Low
Red Flags
- ⚠
Heavy revenue concentration in DefenCath, which accounted for approximately 76% ($97.5M) of Q1 2026 net revenue, making the company vulnerable to product-specific market shifts.
- ⚠
Lack of detailed free cash flow reporting in the provided real-time intelligence, making it challenging to precisely assess long-term capital efficiency despite positive operating cash flow.
- ⚠
The $9.0 million favorable sales-allowance estimate adjustment embedded in DefenCath's Q1 revenue suggests that future revenue may be more susceptible to accounting estimates, which warrants close monitoring.
Upcoming Risk Events
- 📅
Q2 2026 Earnings Miss (estimated early August 2026): A significant miss on revenue or downward revision of FY2026 guidance (currently $325M-$345M) could cause a sharp correction.
- 📅
Slower-than-expected DefenCath Commercial Ramp (ongoing): A slowdown in DefenCath adoption rates or significant negative sales-allowance adjustments impacting net revenue, particularly if quarterly DefenCath revenue stagnates below $90M.
When to Reconsider
- 🚪
Exit if quarterly DefenCath net revenue growth (QoQ) falls below 10% for two consecutive quarters, indicating a significant slowdown in market penetration.
- 🚪
Sell if the company significantly lowers its annual revenue guidance by more than 15% from the current $325M-$345M range.
- 🚪
Exit if cash and short-term investments (currently $178.1M as of March 31, 2026) decline below $100M without clear, identified reasons for strategic investment.
Unlock CRMD Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does CorMedix Inc (CRMD) Do?
Market Cap
$645.66M
Sector
Healthcare
Industry
Biotechnology
Employees
64
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Visit CorMedix Inc WebsiteInvestment Thesis
If CorMedix successfully establishes DefenCath as the undisputed standard of care for catheter-related bloodstream infection prevention in hemodialysis, achieving the upper end of its raised FY2026 revenue guidance of $345M and continuing to grow DefenCath and Melinta portfolio sales by 20%+ annually in FY2027, then its market capitalization could exceed $2.5B (over 3x current levels) within 18-24 months, driven by sustained profitability and pipeline optionality (REZZAYO). This is bullish because the market is underappreciating the rapid adoption and strong margin profile demonstrated in Q1 2026, and the scalability of DefenCath’s distribution.
Is CRMD Stock Undervalued?
Unlock the full AI analysis for CRMD
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
CRMD Price Targets & Strategy
12-Month Target
$35.00
Bull Case
$44.45
Bear Case
$25.40
Valuation Basis
Based on 27x projected FY2026 diluted EPS of $1.27 (derived from midpoint of raised FY2026 net income guidance $100.5M divided by 79.05M shares outstanding).
Entry Strategy
Consider dollar-cost averaging in the range of $8.00-$9.50, accumulating on any dips below $8.50, especially if there's consolidation after recent gains.
Exit Strategy
Take 30% profit at $30-$35, 30% at $40-$45, with a stop-loss order set at $6.50 to protect against unforeseen negative developments.
Portfolio Allocation
7-10% for an aggressive risk tolerance portfolio, given small-cap status and high growth potential.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is CRMD Financially Healthy?
Valuation
P/E Ratio
3.57
Forward P/E
15.80
EV/EBITDA
6.83
PEG Ratio
0.24
Price/Book
9.44
Price/Sales
10.28
Profitability
Gross Margin
85.83%
Operating Margin
48.41%
Net Margin
45.25%
Return on Equity
50.38%
Revenue Growth
384.60%
EPS
$2.10
Balance Sheet
Current Ratio
2.11
Quick Ratio
1.87
Debt/Equity
0.36
Cash & Equivalents
$101.50M
Cash Flow
Operating Cash Flow
$27.30M
Free Cash Flow
$25.80M
EBITDA
$33.80M
Other
Beta (Volatility)
1.51
Does CRMD Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily driven by DefenCath's first-in-class status and QIDP designation, providing market exclusivity. As it establishes itself as the standard of care, healthcare provider inertia and positive patient outcomes will further solidify its position. The growing pipeline also strengthens long-term durability by diversifying product offerings.
Moat Erosion Risks
- •Expiration of DefenCath's QIDP exclusivity or patent protection, allowing for generic competition or similar alternative products.
- •Development of a superior or more cost-effective alternative therapy by a larger pharmaceutical competitor, challenging DefenCath's market dominance.
CRMD Competitive Moat Analysis
Sign up to see competitive advantages
CRMD Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bullish, likely driven by positive Q1 earnings and guidance, but without specific data, it's hard to quantify retail enthusiasm.
Institutional Sentiment
Positive, indicated by the 'Moderate Buy' consensus from analysts and Deep Track's significant 7.94% beneficial ownership, along with participation in major healthcare conferences (RBC, Jefferies).
Insider Activity (Form 4)
No specific Form 4 insider transactions were included in the provided results, so no named insider buys/sells can be verified in the last 90 days.
Options Flow
Normal options activity; no unusual options activity indicating institutional positioning was provided in the search results.
Earnings Intelligence
Next Earnings
Estimated early August 2026 (for Q2 2026 results)
Surprise Probability
Medium, given the Q1 revenue beat but a slight diluted EPS miss against consensus.
Historical Earnings Pattern
Based on Q1 2026, the stock is likely to react positively to strong revenue beats and upward guidance revisions, as commercial execution is now paramount.
Key Metrics to Watch
Competitive Position
Top Competitor
Based on available information, a direct best-in-class competitor with identical product focus is difficult to pinpoint, but in the broader specialty pharma/anti-infectives, companies like Paratek Pharmaceuticals (PRTK) or Pacira BioSciences (PCRX) could be considered, though DefenCath's unique positioning gives CRMD an edge.
Market Share Trend
Gaining significant market share in the specific niche of CRBSI prevention in hemodialysis patients due to DefenCath's first-in-class status and regulatory exclusivity.
Valuation vs Peers
Currently trading at a discount compared to high-growth specialty pharmaceutical companies on forward multiples, particularly given its 226% YoY revenue growth in Q1 2026 and robust profitability. Potential for multiple expansion as execution continues.
Competitive Advantages
- •First-in-class FDA approved DefenCath with QIDP exclusivity for CRBSI prevention.
- •Strong clinical data backing DefenCath's efficacy and safety.
- •Diversifying pipeline (REZZAYO, taurolidine/heparin study) expanding TAM beyond DefenCath.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive CRMD Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (estimated early August 2026): Anticipate continued strong DefenCath adoption and Melinta portfolio contribution; exceeding $100M DefenCath revenue and raising FY2026 guidance again could trigger re-rating.
- •REZZAYO Regulatory Progress (H2 2026): Potential PDUFA date announcement or commercial launch preparations for REZZAYO in prophylaxis for allogeneic stem cell transplant patients, following positive Phase III results, opening a new revenue stream.
Medium-Term (6-18 months)
- •DefenCath European Market Expansion (Q1-Q2 2027): Successful commercialization efforts in key European markets for DefenCath, potentially adding an estimated $50M-$75M in annualized revenue, leveraging existing regulatory approvals.
- •Full Commercial Launch of REZZAYO (H1 2027): Following potential approval, successful market entry and physician uptake of REZZAYO, contributing an estimated $75M-$100M in initial annualized sales, diversifying revenue streams.
Long-Term (18+ months)
- •DefenCath as Standard of Care (2028-2029): Achieving widespread adoption of DefenCath, potentially securing >50% market share in the hemodialysis CRBSI prevention segment, leading to over $500M in annual DefenCath-specific revenue.
- •Pipeline Diversification & Expansion (2029-2030): Positive Phase 3 results and subsequent regulatory approval for the taurolidine/heparin study in TPN patients, expanding the core technology to a new significant indication and patient population.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for CRMD?
- ✓
Watch quarterly DefenCath net revenue growth: sustained QoQ growth above 15% indicates strong market penetration.
- ✓
Monitor net income margin: maintaining or expanding the Q1 2026 net margin of ~30% demonstrates operational efficiency.
- ✓
Track cash from operations: continued positive and growing operating cash flow confirms financial health and self-sustainability.
Bull Case Analysis
Sign up free to see the bull case
Competing with CRMD
See how CorMedix Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
CorMedix Inc CRMD | $645.7M | 8.9 | 3.6 | $91.2M | 45.3% | 384.6% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How CorMedix Inc Makes Money
CorMedix develops and commercializes specialty pharmaceutical products, primarily focused on preventing and treating infectious diseases in acute care and hemodialysis settings. Their flagship product, DefenCath, is a first-in-class antimicrobial catheter lock solution designed to prevent catheter-related bloodstream infections in hemodialysis patients, generating significant revenue. The company also sells a portfolio of anti-infective products acquired from Melinta Therapeutics and is advancing additional pipeline candidates for other supportive care indications, targeting chronic and acute care segments through direct sales to hospitals and dialysis centers.
Read Full Business Model BreakdownFAQ
What is the DVR Score for CorMedix Inc (CRMD)?
As of June 5, 2026, CorMedix Inc has a DVR Score of 8.9 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of CorMedix Inc?
CorMedix Inc's market capitalization is approximately $645.7M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does CorMedix Inc use?
CRMD is the ticker symbol for CorMedix Inc. The company trades on the NGM.
What is the risk level for CRMD stock?
Our analysis rates CorMedix Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of CRMD?
CorMedix Inc currently has a price-to-earnings (P/E) ratio of 3.6. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is CorMedix Inc's revenue growing?
CorMedix Inc has reported revenue growth of 384.6%. The company is showing strong top-line momentum.
Is CRMD stock profitable?
CorMedix Inc has a profit margin of 45.3%. This indicates strong profitability.
How often is the CRMD DVR analysis updated?
Our AI-powered analysis of CorMedix Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 5, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CRMD (CorMedix Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.